SFG
AXSM icon

SVB Financial Group’s Axsome Therapeutics AXSM Stock Holding History

SVB Financial Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-33,849
Closed -$2.72M – 2
2024
Q2 		$2.72M Hold
33,849
– – 1.91% 4
2024
Q1 		$2.7M Hold
33,849
– – 1.49% 5
2023
Q4 		$2.69M Hold
33,849
– – 2.39% 4
2023
Q3 		$2.37M Hold
33,849
– – 4.45% 4
2023
Q2 		$2.43M Hold
33,849
– – 4.6% 4
2023
Q1 		$2.09M Hold
33,849
– – 3.99% 5
2022
Q4 		$2.61M Buy
+33,849
New +$2.02M 7.14% 4

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SVB Financial Group's AXSM Position: Q3 2024 in Review

SVB Financial Group sold out of Axsome Therapeutics (AXSM) in Q3 2024, closing a stake of 33,849 shares — an estimated $2.72M sold.

SVB Financial Group first reported a position in AXSM in Q4 2022 and held it in 7 quarters. The position peaked at $2.72M in Q2 2024. 279 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • SVB Financial Group reported no remaining Axsome Therapeutics position as of Q3 2024 after selling out during the quarter.
  • SVB Financial Group sold 33,849 Axsome Therapeutics shares in Q3 2024, an estimated $2.72M.
  • SVB Financial Group first reported a position in Axsome Therapeutics in Q4 2022 and held it in 7 quarters.
  • SVB Financial Group's Axsome Therapeutics position peaked at $2.72M in Q2 2024.
  • 279 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on SVB Financial Group's 13F filing for Q3 2024, filed 12 Nov 2024.